Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.

Shelan Liu, Min Kang, Na Zhao, Yali Zhuang, Shijian Li, Tie Song
{"title":"Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.","authors":"Shelan Liu,&nbsp;Min Kang,&nbsp;Na Zhao,&nbsp;Yali Zhuang,&nbsp;Shijian Li,&nbsp;Tie Song","doi":"10.1515/mr-2021-0021","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, people all over the world have been affected by coronavirus disease 2019 (COVID-19). Fighting against COVID-19 is the top priority for all the countries and nations. The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic. Three hundred and 44 vaccines were in development, with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022. Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases. However, tough challenges have arisen regarding COVID-19 vaccines, including long-term immunity, emerging COVID-19 variants, and vaccine inequalities. A systematic review was performed of recent COVID-19 vaccine studies, with a focus on vaccine type, efficacy and effectiveness, and protection against SARS-CoV-2 variants, breakthrough infections, safety, deployment and vaccine strategies used in the real-world. Ultimately, there is a need to establish a unified evaluation standard of vaccine effectiveness, monitor vaccine safety and effectiveness, along with the virological characteristics of SARS-CoV-2 variants; and determine the most useful booster schedule. These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations. In the future, global efforts should be directed toward effective and immediate vaccine allocations, improving vaccine coverage, SARS-CoV-2 new variants tracking, and vaccine booster development.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"2 2","pages":"169-196"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/3a/mr-2-2-mr-2021-0021.PMC9274757.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical review (Berlin, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/mr-2021-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Currently, people all over the world have been affected by coronavirus disease 2019 (COVID-19). Fighting against COVID-19 is the top priority for all the countries and nations. The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic. Three hundred and 44 vaccines were in development, with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022. Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases. However, tough challenges have arisen regarding COVID-19 vaccines, including long-term immunity, emerging COVID-19 variants, and vaccine inequalities. A systematic review was performed of recent COVID-19 vaccine studies, with a focus on vaccine type, efficacy and effectiveness, and protection against SARS-CoV-2 variants, breakthrough infections, safety, deployment and vaccine strategies used in the real-world. Ultimately, there is a need to establish a unified evaluation standard of vaccine effectiveness, monitor vaccine safety and effectiveness, along with the virological characteristics of SARS-CoV-2 variants; and determine the most useful booster schedule. These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations. In the future, global efforts should be directed toward effective and immediate vaccine allocations, improving vaccine coverage, SARS-CoV-2 new variants tracking, and vaccine booster development.

Abstract Image

Abstract Image

Abstract Image

对现实世界COVID-19疫苗的综合叙述综述:观点和机遇。
目前,世界各地的人们都受到2019年冠状病毒病(COVID-19)的影响。抗击新冠肺炎疫情是所有国家和民族的当务之急。开发安全有效的COVID-19疫苗被认为是结束大流行的最佳途径。截至2022年3月15日,共有344种疫苗正在开发中,其中149种正在进行临床研究,35种被批准用于紧急使用。许多研究表明,COVID-19疫苗在预防SARS-CoV-2感染以及严重和致命的COVID-19病例方面具有有效作用。然而,在COVID-19疫苗方面出现了严峻挑战,包括长期免疫、新出现的COVID-19变体和疫苗不平等。对最近的COVID-19疫苗研究进行了系统回顾,重点关注疫苗类型、功效和有效性、对SARS-CoV-2变体的保护、突破性感染、安全性、部署和现实世界中使用的疫苗策略。最终,需要建立统一的疫苗有效性评价标准,监测疫苗的安全性和有效性,以及SARS-CoV-2变异体的病毒学特征;确定最有用的助推器时间表。必须协调这些方面,以确保及时对有利或有害的情况作出反应。未来,全球应致力于有效和立即分配疫苗,提高疫苗覆盖率,跟踪新变体,开发疫苗加强剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信